Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

21.6%

33 terminated/withdrawn out of 153 trials

Success Rate

56.0%

-30.6% vs industry average

Late-Stage Pipeline

12%

19 trials in Phase 3/4

Results Transparency

110%

46 of 42 completed trials have results

Key Signals

40 recruiting46 with results30 terminated

Enrollment Performance

Analytics

Phase 1

66(43.7%)

Phase 2

65(43.0%)

Phase 3

18(11.9%)

Phase 4

1(0.7%)

N/A

1(0.7%)

151Total

Phase 1(66)

Phase 2(65)

Phase 3(18)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (153)

Showing 20 of 153 trials

NCT05613894Phase 1Recruiting

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Role: collaborator

NCT07187869Phase 1Recruiting

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Role: collaborator

NCT07489495Phase 3Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Role: collaborator

NCT06943755Phase 2Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Role: lead

NCT07750158Phase 3Not Yet Recruiting

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Role: lead

NCT04919122Active Not Recruiting

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Role: collaborator

NCT05176483Phase 1Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Role: lead

NCT01639508Phase 2Recruiting

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Role: collaborator

NCT07227402Phase 3Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Role: collaborator

NCT05678673Phase 3Active Not Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Role: lead

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT06959511Phase 2Recruiting

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Role: collaborator

NCT05263050Phase 2Recruiting

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Role: collaborator

NCT07043608Phase 2Recruiting

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Role: collaborator

NCT07428616Phase 2Recruiting

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Role: lead

NCT04413123Phase 2Active Not Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Role: collaborator

NCT07714551Phase 2Not Yet Recruiting

Zanzalintinib in Unresectable and Progressive MPGGs

Role: collaborator

NCT04164979Phase 2Completed

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Role: collaborator

NCT05425940Phase 3Active Not Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Role: lead

NCT07218666Phase 2Recruiting

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

Role: collaborator